The Complete Spravato Billing and Coding Guide for Healthcare Providers

Navigating the Spravato billing and coding guide landscape requires a clear understanding of federal drug codes, payer-specific requirements, and the unique clinical oversight rules tied to this medication. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and it carries a billing profile unlike most psychiatric drugs. Because it is administered in a certified healthcare setting under observation, the reimbursement process involves both a drug component and a clinical administration component. Providers who get these billing elements wrong often face claim denials, delayed payments, or compliance risks. This guide breaks down the full billing process in plain, practical terms.

What Is Spravato and Why Does Billing Differ from Other Antidepressants?

Most antidepressants are dispensed at a retail pharmacy and billed under the pharmacy benefit. Spravato works differently. Patients do not take it home. Instead, they come into a certified healthcare setting, self-administer the nasal spray under clinical supervision, and remain on-site for at least two hours for monitoring. This in-office administration model is the reason Spravato is billed as a medical benefit rather than a pharmacy benefit in most cases.

Spravato received FDA approval in March 2019, and Janssen Pharmaceuticals markets it under a Risk Evaluation and Mitigation Strategy (REMS) program. The FDA’s Spravato REMS program requires healthcare settings to be certified before they can dispense and administer the drug. Only enrolled patients treated in certified settings are eligible for treatment, and this certification requirement has direct implications for who can bill for the drug and under what circumstances.

Understanding this structure is the foundation of accurate Spravato billing. The drug itself, the clinical monitoring time, and any evaluation and management (E&M) services provided on the same day each have their own billing path.

HCPCS Codes for Spravato Billing

The primary billing code for Spravato is HCPCS code S0013, which was specifically created for esketamine nasal spray. This code is reported per nasal spray device, and the appropriate number of units depends on the dose administered. Spravato comes in 56 mg and 84 mg doses. A 56 mg dose uses two nasal spray devices (two units of S0013), while an 84 mg dose uses three nasal spray devices (three units).

Some payers, particularly Medicare Advantage plans and commercial insurers, may also cross-reference HCPCS J-codes or require providers to use a specific format for drug claims on CMS-1500 forms. Always verify which code a specific payer prefers, since coding requirements are not universal across all insurance carriers.

For the observation and monitoring services that accompany each Spravato session, providers typically bill CPT code 99213 or 99214 for evaluation and management services if a qualifying E&M service is provided. However, many practices bill CPT code 99211 when only clinical staff supervision occurs, and no physician E&M is performed. For the clinical monitoring observation itself, some providers use CPT 90863 when medication management is integrated into the visit.

The American Medical Association’s CPT code database is the authoritative source for understanding how these procedure codes interact. Providers should consult it alongside payer-specific guidelines to avoid mismatches.

Medicare Coverage for Spravato

Medicare coverage of Spravato falls under Part B, since the drug is administered in a medical setting. This is a significant distinction. If Spravato were a self-administered drug taken at home, it would typically fall under Part D. Because it is administered in a certified setting under supervision, Medicare Part B covers both the drug cost and the associated administration services.

Under Medicare Part B drug billing, the reimbursement rate is generally set at the Average Sales Price (ASP) plus 6%. Medicare sets ASP quarterly, so the reimbursement amount for Spravato fluctuates with each update. Providers can find current ASP data through the Centers for Medicare and Medicaid Services (CMS) drug pricing files.

One critical point for Medicare billing: providers must purchase the drug through Spravato’s limited distribution network and administer it in a REMS-certified setting. Billing Medicare for Spravato without this certification is a compliance violation. Additionally, the “incident to” billing rules apply here. If the administration is supervised by a physician and performed by qualified clinical staff, it may qualify for incident-to billing, but the supervising physician must meet the standard incident-to requirements as defined by CMS.

Medicare beneficiaries are typically responsible for a 20% coinsurance after meeting their Part B deductible. Many patients seek supplemental coverage to offset this cost, which should be discussed during the prior authorization process.

Prior Authorization Requirements

Prior authorization is one of the most time-intensive parts of the Spravato billing and coding process. Nearly all commercial payers and many Medicare Advantage plans require prior authorization before they will cover Spravato. Traditional Medicare does not require prior authorization for Part B drugs in the same way, but coverage criteria still apply.

Commercial payer prior authorization criteria commonly include documentation showing that the patient has a confirmed diagnosis of treatment-resistant depression (meaning they have failed at least two adequate courses of antidepressant therapy) or a diagnosis of major depressive disorder with acute suicidal ideation. Payers typically also require documentation of prior medication trials, including the specific medications tried, doses used, and duration of treatment.

The prior authorization request should include the treating psychiatrist’s clinical notes, the patient’s DSM-5 diagnosis codes, prior treatment history, and a letter of medical necessity if required by the payer. Turnaround times vary widely. Some commercial payers respond within a few business days, while others take two to three weeks. Building this timeline into the patient’s treatment plan is essential to avoid delays that could affect care.

ICD-10 Diagnosis Codes Used in Spravato Claims

Accurate diagnosis coding directly affects whether a claim is approved or denied. The two FDA-approved indications for Spravato map to specific ICD-10 codes that payers expect to see on the claim.

For treatment-resistant depression, the appropriate ICD-10 code is F32.89 (other specified depressive episodes) or F33.8 (other specified depressive disorders), depending on whether the presentation is episodic or recurrent. Some payers also accept F33.2 (major depressive disorder, recurrent, severe without psychotic features) when properly documented.

For major depressive disorder with acute suicidal ideation, the claim should include the appropriate MDD code along with T14.91XA (suicide attempt, initial encounter) or R45.851 (suicidal ideation) to fully capture the clinical picture. The specific combination of codes matters significantly. Payers review diagnosis codes against the approved indication, and mismatched codes are a common cause of denial.

The Centers for Disease Control and Prevention’s ICD-10-CM Official Guidelines provide the authoritative guidance on sequencing and combination coding, and practices should review them annually since codes and guidelines are updated each October.

The Spravato REMS Program and Its Impact on Billing

The REMS program for Spravato is not just a clinical compliance requirement. It has tangible billing implications. A healthcare setting that is not enrolled in the Spravato REMS program cannot legally obtain or administer the drug, which means any claim submitted for services provided outside of REMS certification would be improper.

Under REMS, healthcare settings must enroll directly with Janssen and agree to a set of protocols covering patient monitoring, adverse event reporting, and staff training. The Spravato REMS program website provides enrollment information and required training materials for healthcare settings. Completing enrollment before seeing the first patient is non-negotiable.

REMS compliance also ties into documentation. During each treatment session, clinical staff must document that the patient was monitored for at least two hours, that blood pressure was assessed at appropriate intervals, and that the patient did not drive or operate machinery after the session. This documentation is not only a REMS requirement. It is also the documentation that supports medical necessity, should a payer request records during an audit.

Billing for the Monitoring Session: Administration Codes

Beyond the drug itself, the two-hour monitoring period generates its own billable service. This is where many practices leave revenue on the table or make errors that trigger denials.

The monitoring session is typically billed using CPT 99213 or 99214 if a physician or qualified provider performs a meaningful E&M service during that time. If the monitoring is primarily nursing supervision without direct physician involvement, CPT 99211 may be more appropriate. Some practices also use prolonged service codes when the monitoring time significantly exceeds typical encounter times.

A separate and important consideration is whether the E&M service and the drug administration are billed together on the same claim. Most payers accept this when the services are distinct and separately documented. Using a modifier 25 on the E&M code signals to the payer that the E&M service was significant and separate from the drug administration, reducing the risk of bundling denials.

Documentation is everything in these claims. The clinical record must show what the physician assessed during the monitoring visit, what the patient’s status was before and after administration, and that the monitoring period was completed as required. Incomplete documentation is one of the top reasons Spravato claims are audited or denied.

Handling Denials and Appeals

Even well-prepared Spravato claims get denied. Common reasons include missing prior authorization numbers on the claim, incorrect unit counts for the drug code, mismatched diagnosis codes, and failure to document REMS compliance. Understanding why a denial occurred is the first step toward a successful appeal.

When a claim is denied for lack of medical necessity, the appeal should lead with clinical documentation. A detailed letter from the treating psychiatrist explaining the patient’s treatment history, failed prior therapies, and current diagnosis is often the most persuasive element in an appeal. Including peer-reviewed literature supporting the use of esketamine in treatment-resistant depression can also strengthen the case.

For denials related to coding errors, submitting a corrected claim rather than a formal appeal is often faster. A corrected claim must be submitted with the appropriate claim frequency code to indicate it replaces the original submission. Billing teams should track denial patterns over time. If the same code or the same payer consistently generates denials, that signals a systemic problem worth investigating.

Spravato Billing and Coding Guide for Commercial Payers

Commercial payer requirements for Spravato vary more than Medicare requirements. Some large commercial insurers cover Spravato under the medical benefit using a process similar to Medicare. Others route it through specialty pharmacy, which changes the billing model entirely.

When a commercial payer routes Spravato through specialty pharmacy, the healthcare setting may receive the drug through a buy-and-bill arrangement or may receive it directly from the specialty pharmacy. In a buy-and-bill model, the practice purchases the drug and then bills the payer for both the drug and the administration. In a specialty pharmacy model, the pharmacy bills for the drug separately, and the practice only bills for the clinical services.

Understanding which model applies to each payer is essential before starting treatment. Billing for the drug under buy-and-bill when the payer expects a specialty pharmacy claim will result in a denial. Practices managing multiple payers need a tracking system that maps each payer’s preferred billing approach to the appropriate billing workflow.

Documentation Best Practices for Spravato Claims

Clean documentation is the difference between a paid claim and an audit headache. For each Spravato session, the clinical record should include the patient’s diagnosis with ICD-10 codes, the specific dose administered, the time the session started and ended, nursing notes from the monitoring period, blood pressure readings taken before and after administration, any adverse reactions observed, and confirmation that the patient was assessed as safe to leave.

Physician notes should clearly tie the Spravato treatment to the approved indication. Generic notes that simply say “patient tolerated treatment well” are not sufficient. The note should reflect clinical thinking, including any response assessment, any dose adjustments considered, and any plan changes. This level of documentation supports medical necessity, satisfies REMS requirements, and creates a defensible record if the claim is ever reviewed.

Practices should also maintain a log of each treatment session tied to the REMS program’s monitoring requirements. Separate from the clinical note, this log tracks the specific monitoring checkpoints completed during each session and serves as a quick reference during payer audits.

Common Billing Mistakes to Avoid

Several mistakes surface repeatedly across practices billing for Spravato. Reporting incorrect units for S0013 based on the dose administered is among the most frequent errors. A 56 mg dose requires two units and an 84 mg dose requires three units. Reporting only one unit regardless of dose is a common underbilling error, while reporting excess units leads to overpayment and potential recoupment.

Another common issue is failing to append modifier 25 to the E&M code when it is billed on the same day as the drug administration. Without this modifier, some payers will bundle the E&M into the administration fee and pay only for one service.

Submitting claims without a valid prior authorization number, or with an expired authorization, is another preventable denial cause. Authorization tracking should be built into the practice’s scheduling workflow so that a patient is never seen for a Spravato session without an active, verified authorization on file.

Finally, failing to update fee schedules for S0013 when CMS releases new ASP data each quarter results in either leaving money uncollected or billing above the allowable amount. Quarterly reviews of the CMS ASP update are a routine billing task for any practice administering Spravato.

Conclusion

Accurate Spravato billing requires attention to detail across multiple fronts: the drug code, the clinical administration code, the diagnosis codes, the prior authorization documentation, and ongoing REMS compliance. Each element connects to the others, and a gap in any one area can disrupt reimbursement. Practices that invest in staff training, build clear workflows for each payer, and maintain thorough documentation consistently see better claim approval rates and fewer audit findings. This medication treats patients with serious, difficult-to-treat depression, and getting the billing right ensures those patients continue to have access to care.

Note: Billing and coding guidelines are subject to change. Providers should verify current codes, payer policies, and CMS pricing data regularly and consult with a qualified healthcare billing professional when uncertain about specific claim requirements.

Frequently Asked Questions

What HCPCS code is used to bill for Spravato? 

Spravato is billed using HCPCS code S0013, reported per nasal spray device with units based on the dose administered.

Does Medicare cover Spravato under Part B or Part D? 

Medicare covers Spravato under Part B because it is administered in a certified healthcare setting under clinical supervision, not self-administered at home.

Is prior authorization required for Spravato? 

Most commercial payers and many Medicare Advantage plans require prior authorization; traditional Medicare Part B does not require prior authorization but does apply coverage criteria.

What modifier should be appended to the E&M code when billed on the same day as Spravato administration? 

Modifier 25 should be appended to the E&M code to indicate it was a significant and separately identifiable service from the drug administration.